Stryker (NYSE:SYK) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Stryker (NYSE:SYK) issued its quarterly earnings results on Thursday. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03), FiscalAI reports. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter in the prior year, the firm earned $3.19 earnings per share. The company’s revenue was up 7.6% on a year-over-year basis.

Here are the key takeaways from Stryker’s conference call:

• Hip and knee weakness pressured results: Stryker said the large-joint market has slowed to roughly 2.5% growth, citing affordability concerns, insurance-related preauthorization denials and softer international conditions. The company also acknowledged that cyber and SAP implementation disruptions hurt commercial execution and new-product adoption.
• Stryker lowered its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, reflecting weaker hip and knee trends, lingering peripheral vascular supply constraints and a more conservative view of capital-equipment execution.
• Margins and cash generation remained strong: Third-quarter adjusted EPS rose 10.3% to $3.52, adjusted operating margin expanded 60 basis points to 26.2%, and year-to-date operating cash flow increased about 14% to $3.3 billion. The board also authorized an additional $3 billion for share repurchases.
• MedSurg and Neurotechnology grew 9.1%, led by Endoscopy, Medical and Vascular, while capital demand and the order book remained elevated. Stryker expects strong fourth-quarter contributions from Trauma and Extremities, Medical and Instruments, and highlighted upcoming growth drivers including AVS, new power-tool and endoscopy platforms, Mako products and the CMR Surgical robotics partnership.

Stryker Price Performance

NYSE:SYK traded down $16.04 during trading hours on Friday, hitting $295.71. The stock had a trading volume of 3,552,257 shares, compared to its average volume of 2,459,289. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker has a one year low of $267.00 and a one year high of $389.33. The firm has a market capitalization of $113.43 billion, a price-to-earnings ratio of 30.64, a P/E/G ratio of 1.96 and a beta of 0.78. The company has a 50 day simple moving average of $293.56 and a two-hundred day simple moving average of $324.86.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is currently 36.48%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Sanford C. Bernstein reiterated a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. Evercore set a $350.00 price objective on shares of Stryker in a report on Monday, July 6th. Stifel Nicolaus dropped their target price on Stryker from $360.00 to $330.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Needham & Company LLC lowered their price target on Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a report on Friday. Finally, Barclays cut their price target on Stryker from $375.00 to $365.00 and set an “overweight” rating on the stock in a research note on Friday. Seventeen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $360.08.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6% to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also highlighted strength in the MedSurg business, margin improvement and continued investment in surgical robotics. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Several analysts remain constructive, but lowered their expectations: BTIG Research reduced its target to $304 while keeping a Buy rating, and Citizens JMP cut its target to $390 while retaining Market Outperform. Canaccord Genuity downgraded the stock to Hold and lowered its target to $300, signaling more limited near-term upside. Stryker analysts cut their forecasts
• Negative Sentiment: Quarterly adjusted EPS of $3.52 missed the roughly $3.55–$3.56 consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The company cited softer joint-replacement demand, manufacturing and vascular supply disruptions, and lingering operational effects from its cybersecurity incident. SYK Q3 earnings call highlights
• Negative Sentiment: Stryker cut its 2026 organic sales-growth forecast to 6.5%–7.0% from 8.3%–9.3% and reduced adjusted EPS guidance to $14.80–$14.90 from $14.95–$15.10. The reset, combined with a new CEO taking over amid the challenges, has increased uncertainty about the company’s 2027 starting point. Stryker lowers outlook after third-quarter profit falls

Insider Activity

In other Stryker news, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.